James E. Hansen, MD, MS
Associate Professor of Therapeutic RadiologyDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Gamma Knife Program, Therapeutic Radiology
Radiation Safety, Therapeutic Radiology
Co-Director, Stereotactic Radiosurgery and Body Radiotherapy Fellowship, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Gamma Knife Program, Therapeutic Radiology
Radiation Safety, Therapeutic Radiology
Co-Director, Stereotactic Radiosurgery and Body Radiotherapy Fellowship, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief, Gamma Knife Program, Therapeutic Radiology
Radiation Safety, Therapeutic Radiology
Co-Director, Stereotactic Radiosurgery and Body Radiotherapy Fellowship, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
About
Titles
Associate Professor of Therapeutic Radiology
Chief, Gamma Knife Program, Therapeutic Radiology; Radiation Safety, Therapeutic Radiology; Co-Director, Stereotactic Radiosurgery and Body Radiotherapy Fellowship, Therapeutic Radiology
Biography
Clinical areas of expertise are Gamma Knife stereotactic radiosurgery, SBRT, Central Nervous System, Head and Neck, Lung, Lymphoma, Skin, GI, GU.
Appointments
Therapeutic Radiology
Associate Professor on TermPrimary
Other Departments & Organizations
- Center for Gastrointestinal Cancers
- Center for Thoracic Cancers
- Central Nervous System Radiotherapy
- Head & Neck Radiotherapy
- Head and Neck Cancers Program
- Prostate & Genitourinary Radiotherapy
- Prostate & Urologic Cancers Program
- Radiobiology
- Radiobiology and Genome Integrity
- Spine Oncology Program
- Therapeutic Radiology
- Thoracic Radiotherapy
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Chief Resident
- Yale School of Medicine (2012)
- Resident
- Yale School of Medicine (2011)
- Intern
- Sacred Heart Medical Center (2008)
- Postdoctoral Scholar
- UCLA (2007)
- MD
- UCLA School of Medicine (2004)
- MS
- University of California, Los Angeles, Biochemistry and Molecular Biology (1999)
Research
Overview
Medical Research Interests
Immune System Diseases; Neoplasms; Therapeutics
Research at a Glance
Yale Co-Authors
Frequent collaborators of James E. Hansen's published research.
Publications Timeline
A big-picture view of James E. Hansen's research output by year.
Research Interests
Research topics James E. Hansen is interested in exploring.
Veronica Chiang, MD, FAANS
James B. Yu, MD, MHS, FASTRO
Caroline Helen Johnson, PhD
Henry S. Park, MD, MPH
Sanjay Aneja, MD
Christopher J. Tien, PhD, DABR, FAAPM
43Publications
1,249Citations
Publications
2024
Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy
Cao F, Tang C, Chen X, Tu Z, Jin Y, Turk O, Nishimura R, Ebens A, Dubljevic V, Campbell J, Zhou J, Hansen J. Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy. ACS Central Science 2024, 10: 1562-1572. PMID: 39220699, PMCID: PMC11363321, DOI: 10.1021/acscentsci.4c00559.Peer-Reviewed Original ResearchAltmetricConceptsAntinuclear antibodiesCancer therapyTumor-specific surface antigenLysosomal protease cathepsin BAntibody-drug conjugatesNecrotic tumorTumor environmentExtracellular nucleic acidsSurface antigensProtease cathepsin BCancer cellsTumorNucleoside salvage pathwayDrug linkersNucleoside salvageTherapyCross membrane barriersMembrane barrierCathepsin BLiving cancer cellsDNA guidesAntinuclearSalvage pathwayCathepsinNuclear penetrationNuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation
May C, Noble P, Herzog E, Meffre E, Hansen J. Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation. Biochemical And Biophysical Research Communications 2024, 720: 150123. PMID: 38759301, DOI: 10.1016/j.bbrc.2024.150123.Peer-Reviewed Original ResearchCitationsConceptsDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAnti-topoisomerase 1Systemic lupus erythematosusDiscovery of autoantibodiesMechanisms of autoimmunityInhibit DNA repairScleroderma autoantibodiesScleroderma subtypeSystemic sclerosisLupus erythematosusAutoantibodiesCancer therapyPathophysiologyReagent resourcesCellular dysfunctionAntibodiesCell nucleiDNA repair
2023
Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective Study
Mange A, Singh C, Theriault B, Hansen J, An Y, Aneja S, Chiang V. Selected-Lesion Stereotactic Radiosurgery in Treatment of Patients with Multiple Brain Metastases: A Single Institution Retrospective Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e135. DOI: 10.1016/j.ijrobp.2023.06.939.Peer-Reviewed Original ResearchConceptsMultiple brain metastasesBrain metastasesStereotactic radiosurgeryMedian KPSCommon indicationTumor characteristicsClinical trialsSRS treatmentSingle-institution retrospective studySubsequent-line treatmentMethods Clinical dataPatient selection criteriaTreatment of patientsSubset of lesionsNumber of lesionsDiagnosis of melanomaCNS progressionCNS radiationPrior WBRTOverall survivalPalliative treatmentPatient characteristicsProgressive diseaseImmunotherapy trialsSurvival groupCellular protection from H2O2 toxicity by Fv-Hsp70: protection via catalase and gamma-glutamyl-cysteine synthase
Hino C, Chan G, Jordaan G, Chang S, Saunders J, Bashir M, Hansen J, Gera J, Weisbart R, Nishimura R. Cellular protection from H2O2 toxicity by Fv-Hsp70: protection via catalase and gamma-glutamyl-cysteine synthase. Cell Stress And Chaperones 2023, 28: 429-439. PMID: 37171750, PMCID: PMC10352194, DOI: 10.1007/s12192-023-01349-6.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsHeat shock proteinsGamma-glutamylcysteine synthaseCellular protectionAcute oxidative stressLid domainProtein-binding domainsATPase domainCysteine synthaseOxidative stressCellular stressRecombinant proteinsSH-SY5Y cellsEndogenous heat shock proteinsShock proteinsCell deathProteinProtein catalaseHSP70H2O2 toxicityCellsSynthaseΜM concentrationsDomainCatalaseDirect response
2022
Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA Autoantibody
Chen X, Cuffari BJ, Dubljevic V, Shirali A, Zhou J, Campbell JA, Suits SC, O'Sullivan KM, Hansen JE. Inhibition of NETosis by a Nuclear-Penetrating Anti-DNA Autoantibody. ImmunoHorizons 2022, 6: 356-365. PMID: 35697479, DOI: 10.4049/immunohorizons.2100091.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeutrophil extracellular trapsAnti-DNA autoantibodiesRelease of NETsInhibition of NETosisOncology clinical trialsDifferentiated PLB-985 cellsMechanisms of NETosisCalcium ionophore ionomycinPLB-985 cellsIndependent NETosisC57BL/6 miceClinical trialsExtracellular trapsSuch AbsAutoantibodiesNeutrophil biologyDNA damage responseTherapeutic potentialNETosisHistone citrullinationIonophore ionomycinWestern blotSignificant inhibitionMultiple diseasesNeutrophils
2021
Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones
Glauzy S, Olson B, May CK, Parisi D, Massad C, Hansen JE, Ryu C, Herzog EL, Meffre E. Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones. Arthritis & Rheumatology 2021, 74: 307-317. PMID: 34279059, PMCID: PMC8766600, DOI: 10.1002/art.41927.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsB cell tolerance checkpointsEarly B cell tolerance checkpointsPeripheral B cell tolerance checkpointsNaive B cellsMature naive B cellsSystemic sclerosisTransitional B cellsTolerance checkpointsB cellsHealthy donorsAutoreactive mature naive B cellsAutoreactive naive B cellsAntigen-specific B cellsCentral B cell toleranceB cell toleranceB cell productionAntigen-specific clonesReactivity of antibodiesSingle B cellsSSc patientsSerum autoantibodiesAutoimmune diseasesImmune complexesPatientsCell toleranceRecognition and Management of Adverse Radiation Effects
Cheok S, Hansen J, Chiang V. Recognition and Management of Adverse Radiation Effects. 2021, 391-404. DOI: 10.1201/9781003167464-36.ChaptersConceptsAdverse radiation effectsRadiation necrosisStereotactic radiosurgeryRole of SRSImmune-mediated componentLaser interstitial thermotherapyMore brain lesionsBrain metastasesSystemic therapyIntracranial pathologyMalignant pathologyBrain lesionsNecrosisInterstitial thermotherapyPathologyContemporary evidenceBevacizumabCraniotomyMetastasisTherapyLesionsRadiosurgerySteroidsENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody
Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, Cuffari BJ, Liu J, Zou P, Rattray N, Johnson CH, Dubljevic V, Campbell JA, Huttner A, Baehring JM, Zhou J, Hansen JE. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight 2021, 6: e145875. PMID: 34128837, PMCID: PMC8410084, DOI: 10.1172/jci.insight.145875.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBlood-brain barrierAnti-DNA autoantibodiesBrain tumorsBreast cancer brain metastasesBlood-brain barrier transportBrain tumor immunotherapyCancer brain metastasesBrain endothelial cellsEndothelial cell penetrationCNS lupusNeurotoxic autoantibodiesBrain metastasesTumor immunotherapyBarrier transportAntibody-based approachesCNS penetrationAutoantibodiesEfficacy studiesOrthotopic glioblastomaEndothelial cellsTumorsCancer cellsNucleoside fluxesActionable mechanismsKey transportersChapter 48 Malignancies in systemic lupus erythematosus
Ladouceur A, Tissera H, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 48 Malignancies in systemic lupus erythematosus. 2021, 461-467. DOI: 10.1016/b978-0-12-814551-7.00048-9.ChaptersConceptsSystemic lupus erythematosusSLE patientsLupus erythematosusGeneral populationOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPotential reasonsLymphomaMalignancyPathophysiologyPopulationBreastImpact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas.
Peters GW, Tien CJ, Chiang V, Yu J, Hansen JE, Aneja S. Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas. Journal Of Radiosurgery And SBRT 2021, 7: 207-212. PMID: 33898084, PMCID: PMC8055239.Peer-Reviewed Original ResearchCitationsConcepts
Clinical Trials
Current Trials
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RoleSub InvestigatorPrimary Completion Date01/31/2030Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Therapeutic Radiology
Fact Sheets
Stereotactic Body Radiotherapy (SBRT)
Learn More on Yale MedicineBrachytherapy
Learn More on Yale MedicinePrimary Brain Tumors
Learn More on Yale MedicineMetastatic Brain Tumors
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- July 16, 2024Source: Newsweek
Cancer breakthrough as Yale radiologists develop 'Trojan Horse' therapy
- May 08, 2024
James Hansen, MD, MS, in honor of Brain Tumor Awareness Month
- September 26, 2022
Fighting Breast and Ovarian Cancer With a Lupus Antibody
- July 06, 2022Source: YaleNews
Insights & Outcomes: Biofilms, cravings, and cells that spill their guts
Get In Touch
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Locations
Yale Therapeutic Radiology
Academic Office
Hunter Building
15 York Street, Ste HRT 313A
New Haven, CT 06510
Appointments
203.200.2000Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.